Needham & Company Cuts Price Target on Flexion Therapeutics (FLXN) Following Top-Line FX006 Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Needham & Company Cuts Price Target on Flexion Therapeutics (FLXN) Following Top-Line FX006 Data
September 8, 2015 5:33 PM EDT
Tetraphase Pharma (NASDAQ: TTPH) 79.5% LOWER; announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections (cUTI) did not achieve its primary endpoint of statistical non-inferiority compared to levofloxacin.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) 61.3% HIGHER; announced positive top-line results from its Phase 2 study of vadadustat (formerly AKB-6548) in dialysis patients with anemia related to chronic kidney disease (CKD). The study achieved its primary objective, indicating that vadadustat maintained stable... More
September 8, 2015 5:26 PM EDT
Ampio Pharma (NYSE: AMPE) was mentioned cautiously in connection with Flexion Therapeutics' (NASDAQ: FLXN) failed FX006 trial. Given the blow up, Ampio Pharma should trade at zero, said theStreet.com's Adam Feuerstein.
Given the $FLXN blow up, $AMPE should trade at zero. Literally, zero.
Adam Feuerstein (@adamfeuerstein)
September 8, 2015
...
More
September 8, 2015 4:07 PM EDT
Flexion Therapeutics (NASDAQ: FLXN) reported top-line results from the first of two pivotal clinical trials of its lead drug candidate FX006 in patients with moderate to severe osteoarthritis (OA) knee pain. In this trial, 40 mg of FX006, compared to placebo (saline), demonstrated statistical significance in average pain relief over weeks 1 through 12 (p = 0.0012; 2-sided) and over weeks 1 through 24 (p = 0.0209; 2-sided). At weekly time points, 40 mg of FX006 also demonstrated superiority to placebo in pain relief beginning at week 1, continuing to week 11 and also at week 13 (p... More
